» Articles » PMID: 8189509

Uncoating of Human Rhinovirus Serotype 2 from Late Endosomes

Overview
Journal J Virol
Date 1994 Jun 1
PMID 8189509
Citations 81
Authors
Affiliations
Soon will be listed here.
Abstract

The internalization pathway and mechanism of uncoating of human rhinovirus serotype 2 (HRV2), a minor-group human rhinovirus, were investigated. Kinetic analysis revealed a late endosomal compartment as the site of capsid modification from D to C antigenicity. The conformational change as well as the infection was prevented by the specific V-ATPase inhibitor bafilomycin A1. A requirement for ATP was also demonstrated with purified endosomes in vitro. Capsid modifications occurred at a pH of 5.5 regardless of whether the virus was entrapped in isolated endosomes or free in solution. These findings suggest that the receptor is not directly involved in the structural modification of HRV2. Viral particles found in purified endosomes of infected cells were mostly devoid of RNA. This supports the hypothesis that uncoating of HRV2 occurs in intact endosomes rather than by a mechanism involving endosomal disruption with subsequent release of the RNA into the cytoplasm.

Citing Articles

Virus-Receptor Interactions and Receptor-Mediated Virus Entry into Host Cells.

Casasnovas J Subcell Biochem. 2024; 105:533-566.

PMID: 39738957 DOI: 10.1007/978-3-031-65187-8_15.


Endosome rupture enables enteroviruses from the family Picornaviridae to infect cells.

Ishemgulova A, Mukhamedova L, Trebichalska Z, Rajecka V, Payne P, Smerdova L Commun Biol. 2024; 7(1):1465.

PMID: 39511383 PMC: 11543853. DOI: 10.1038/s42003-024-07147-9.


p38 Mitogen-Activated Protein Kinase Signaling Enhances Reovirus Replication by Facilitating Efficient Virus Entry, Capsid Uncoating, and Postuncoating Steps.

Mohamed A, Lin Q, Eaton H, Shmulevitz M J Virol. 2023; 97(2):e0000923.

PMID: 36744961 PMC: 9972948. DOI: 10.1128/jvi.00009-23.


Hijacking Host Immunity by the Human T-Cell Leukemia Virus Type-1: Implications for Therapeutic and Preventive Vaccines.

Pise-Masison C, Franchini G Viruses. 2022; 14(10).

PMID: 36298639 PMC: 9609126. DOI: 10.3390/v14102084.


Rhinovirus Inhibitors: Including a New Target, the Viral RNA.

Real-Hohn A, Blaas D Viruses. 2021; 13(9).

PMID: 34578365 PMC: 8473194. DOI: 10.3390/v13091784.


References
1.
LONBERG-HOLM K, Gosser L, Shimshick E . Interaction of liposomes with subviral particles of poliovirus type 2 and rhinovirus type 2. J Virol. 1976; 19(2):746-9. PMC: 354908. DOI: 10.1128/JVI.19.2.746-749.1976. View

2.
Willingmann P, Barnert H, Zeichhardt H, HABERMEHL K . Recovery of structurally intact and infectious poliovirus type 1 from HeLa cells during receptor-mediated endocytosis. Virology. 1989; 168(2):417-20. DOI: 10.1016/0042-6822(89)90286-9. View

3.
Gruenberger M, Pevear D, Diana G, Kuechler E, Blaas D . Stabilization of human rhinovirus serotype 2 against pH-induced conformational change by antiviral compounds. J Gen Virol. 1991; 72 ( Pt 2):431-3. DOI: 10.1099/0022-1317-72-2-431. View

4.
Laemmli U . Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227(5259):680-5. DOI: 10.1038/227680a0. View

5.
Bowman E, Siebers A, Altendorf K . Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells. Proc Natl Acad Sci U S A. 1988; 85(21):7972-6. PMC: 282335. DOI: 10.1073/pnas.85.21.7972. View